Early changes in arterial structure and function following statin initiation: Quantification by magnetic resonance imaging  by Lee, Justin M.S. et al.
Ai
r
s
d
L
a
c
b
©
K
1
d
w
o
s
1
i
d
s
4
a
R
0
dAtherosclerosis 197 (2008) 951–958
Early changes in arterial structure and function following statin
initiation: Quantification by magnetic resonance imaging
Justin M.S. Lee 1, Frank Wiesmann 1, Cheerag Shirodaria, Paul Leeson,
Steffen E. Petersen, Jane M. Francis, Clare E. Jackson, Matthew D. Robson,
Stefan Neubauer, Keith M. Channon, Robin P. Choudhury ∗
Department of Cardiovascular Medicine, University of Oxford, United Kingdom
Received 16 May 2007; received in revised form 22 August 2007; accepted 4 September 2007
Available online 30 October 2007
bstract
Effective LDL-cholesterol (LDL-C) reduction improves vascular function and can bring about regression of atherosclerosis. Alterations
n endothelial function can occur rapidly, but changes in atherosclerosis are generally considered to occur more slowly. Vascular magnetic
esonance imaging (MRI) is a powerful technique for accurate non-invasive assessment of central and peripheral arteries at multiple anatomical
ites. We report the changes in atherosclerosis burden and arterial function in response to open label statin treatment, in 24 statin-naı¨ve newly
iagnosed stable coronary artery disease patients. Patients underwent MRI before, and 3 and 12 months after commencing treatment. Mean
DL-C fell by 37% to 70.8 mg/dL (P < 0.01). The plaque index (normalised vessel wall area) showed reductions in the aorta (2.3%, P < 0.05)
nd carotid (3.1%, P < 0.05) arteries at 3 months. Early reductions in atherosclerosis of aorta and carotid observed at 3 months were significantly
orrelated with later change at 12 months (R2 = 0.50, P < 0.001; R2 = 0.22, P < 0.05, respectively). Improvements in aortic distensibility and
rachial endothelial function that were apparent after 3 months treatment were sustained at the 12-month time point.
2007 Published by Elsevier Ireland Ltd.
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. Introduction
HMG CoA reductase inhibitors or ‘statins’ reduce car-
iovascular events by approximately 25–30% in patients
ith stable atherosclerotic disease [1,2]. Previous studies
f ultrasound carotid intima media thickness (CIMT) have
uggested relatively slow regression of atherosclerosis after
–2 years of high dose statin treatment [3,4]. More recently,
ntravascular ultrasound (IVUS) of the coronary arteries has
emonstrated coronary plaque regression following inten-
ive LDL-C reduction in over 300 patients treated with
0 mg rosuvastatin for 2 years [5]. Corti et al. [6] were
mong the first to use serial magnetic resonance imag-
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Open access under CC BY ling (MRI), to demonstrate reduction in carotid and aortic
therosclerosis in 18 patients in response to 12 months of
tatin treatment. Subsequently, the same group demonstrated
hat more effective lipid lowering, to LDL-C < 100 mg/dL,
as associated with a larger decrease in plaque size at 12
onths [7]. Similarly, Saam et al. [8] have recently identi-
ed statin treatment as an independent predictor of reduced
nnual rate of carotid atheroma progression, measured using
RI.
In the setting of acute coronary syndromes, early initiation
f ‘intensive’ statin treatment can rapidly reduce cardiovas-
ular risk within 4–16 weeks [9,10]. However, given the
pparently slow changes in atheroma burden observed in
revious studies [6], it has been hypothesised that the early
linical benefits of statins cannot reflect structural changes
ithin arteries, but are due to ‘pleiotropic’ effects of statins
uch as improvement in endothelial function and reduction in
nflammation and thrombosis [11]. Indeed, numerous studies
cense.
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ave demonstrated rapid improvement in endothelial function
n response to statin treatment [12–14]. However, there is also
vidence that rapid changes in plaque size and composition
ight also be possible. Animal models of atherosclerosis
ndicate that potent correction of dyslipidaemia can result
n prompt regression and favourable remodelling of plaques
fter only 9 weeks [15]. Furthermore, in humans, a recent
tudy of treatment with intravenous apoAI-Milano induced
odest but significant regression of coronary atherosclerosis
fter only 6 weeks [16].
We have previously shown that MRI can assess both
entral and peripheral vascular function, including measure-
ents of arterial stiffness and endothelial function [17,18].
hese parameters are of additional interest because they
ave been shown prospectively to predict cardiovascular
isk [19,20]. By assessing both atherosclerosis and vascu-
ar function in the same patients we hoped to examine the
xtent to which changes in structural parameters might be
nticipated by early functional changes. In this study, we
sed magnetic resonance imaging to evaluate, in vivo, the
hanges in structure and function in human aorta, carotid and
rachial arteries at 0, 3 and 12 months in response to statin
herapy. Notably, the mean post-treatment LDL-C achieved
n this study reached the contemporary target of 70 mg/dL
21].
. Methods
.1. Study population
Newly diagnosed patients (n = 32) with coronary artery
isease were recruited from the Cardiology Department of
single tertiary centre. Diagnosis was based on a history
f typical symptoms of angina together with an exercise
CG that showed ischaemic-type ST segment changes or
stenosis of ≥50% in at least one coronary artery at
ngiography. No patients had taken statins prior to study
nrolment. No other cholesterol modifying agents were per-
itted, but no further restrictions were placed on concomitant
ardiovascular medications. Patients with acute coronary
yndromes or contra-indication to MRI were excluded. MRI
as performed at baseline, 3 and 12 months. At each
ime point, venous blood samples were obtained after a
2-h fast. Statin treatment was withheld until immediately
fter the first MRI scan, when a statin was started accord-
ng to the preference of the managing clinician. Decisions
egarding cholesterol treatment and management of cardiac
isk factors were taken by the responsible clinicians. Statin
ose titration, whilst allowed, was not protocol-driven. The
tudy protocol was approved by the local Research Ethics
ommittee and all subjects gave informed written consent.
f the 32 subjects initially recruited, 8 did not complete
ll three study time points: 1 patient died from an out
f hospital cardiac arrest, 5 were unwilling to return for
ollow-up scans due to claustrophobia and 2 were lost to
a
f
a
iis 197 (2008) 951–958
ollow-up. The 8 patients who did not complete the study
ere not significantly different from the 24 who did in
erms of either their risk factors (age, cholesterol, diabetes,
ypertension and smoking) or MRI measures of atheroma
r vascular function at baseline. The data reported below
efer to the 24 patients, who completed the study proto-
ol.
.2. Vascular MRI protocol
Imaging was performed on a 1.5 T magnetic resonance
canner (Siemens Sonata, Erlangen, Germany) as previously
escribed [17,18]. In brief, aortic imaging was performed
sing a combination of a two-element array surface coil
laced on the chest and spine coil array. For carotid artery
maging, a two-element array surface coil was used (Mach-
et BV, Eelde, Netherlands) and for brachial artery imaging
surface coil was attached at the right elbow. Brachial artery
lood pressure was monitored using a blood pressure cuff
n the left arm. For quantification of aortic wall area, ECG-
ated double-inversion recovery (black-blood) fast spin echo
mages were acquired during breath-hold (Figs. 1b and 2b).
ypical parameters were FOV 200 mm, TR 750 ms, TE
1 ms, in plane resolution 0.8 mm × 0.8 mm, slice thickness
mm. Using an oblique sagittal image of the aorta as a pilot,
1 serial axial images were acquired with 5 mm interslice
ap to cover the entire descending thoracic aorta. The mid-
oint of the right pulmonary artery in cross section was used
s the anatomical reference for the first slice in baseline
nd follow-up scans. For the carotid arteries axial ECG-
ated T2 weighted, black blood images of the neck were
cquired during free breathing (Fig. 2b). Sequence parame-
ers: FOV 150 mm, TR 2 R–R intervals, TE 81 ms, resolution
.5 mm × 0.5 mm in plane, slice thickness 3 mm, no inter-
lice gap. Nine images of the common carotid artery were
cquired using the common carotid bifurcation as the anatom-
cal reference position for baseline and follow-up scans. Care
as taken to place aortic and carotid image slices perpendic-
lar to the long axis of the vessel on the pilot images in
rder to limit partial volume effects. For analysis of aorta
nd carotid plaque images all identifying data were removed
part from a code number so that observers were blinded to
oth patient identity and study time point. The external ves-
el boundary and vessel lumen were contoured manually by
ne of two experienced observers (J.L., C.S.) using CMR-
ools software (Imperial College, London, UK). Vessel wall
rea was calculated from the difference between these two
ontours, and then normalised to external vessel area to yield
plaque index (PI), as previously described [22,23]. Plaque
ndex for each patient was then expressed as the mean of all
ortic or carotid slices. In keeping with previous studies of
arotid atherosclerosis, a mean value was obtained for left
nd right carotid arteries combined [3,4]. A subset of images
rom four randomly selected patients (>100 images) were
nalysed by both observers to assess inter-observer variabil-
ty.
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Fig. 1. (a) Plaque index in the aorta is reduced in response to statin treatment. Significant reductions were observed between baseline and 3 months and between
3 and 12 months (* indicates P < 0.05 vs. baseline, † indicates P < 0.05 vs. 3 months). (b) Proton density weighted image of descending thoracic aorta showing
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orrelated to the change measured at 12 months.
Steady state free precession (SSFP) acquisitions were
sed to determine aortic distensibility and brachial artery
eactivity, as previously described [17,18]. Post processing
f aortic and brachial images was performed using semi-
utomated edge detection methods developed with Matlab
oftware (Mathworks Inc.) [24]. Maximum and minimum
ortic cross-sectional areas over the cardiac cycle were mea-
ured, from which distensibility was calculated as the relative
hange in area divided by the pulse pressure. To assess
rachial artery flow mediated dilatation (FMD), cross sec-
ional images of the brachial artery were acquired at baseline
nd following release of a cuff inflated to 50 mmHg above
ystolic blood pressure on the forearm for 5 min. After
0 min, further brachial artery images were acquired follow-
ng administration of 400g of sublingual glyceryl trinitrate
o elicit maximal (endothelial-independent) dilatation. Max-
mum percentage change in cross sectional area was used to
etermine the response to each stimulus.
.3. Serum and plasma assaysCholesterol and lipoprotein assays were performed using
Cobas-Mira Analyser (ABX Diagnostics, Shefford, UK).
otal cholesterol was assayed using the enzymatic CHOD-
c
a
r
P(arrow). (c) Change in plaque index (ΔPI) at 3 months was significantly
AP method and triglycerides were assayed using the
nzymatic GPO-PAP method. HDL-cholesterol was assayed
sing a homogenous second generation PEGME method
Roche Diagnostics, Burgess Hill, UK). Apolipoprotein AI
apoAI) and apolipoprotein B (apoB) were assayed using
mmunoturbidimetric methods, using reagents supplied by
BX Diagnostics. C-reactive protein was analysed using
LISA (MP Biomedicals, UK) according to the manufac-
urer’s instructions.
.4. Statistical analyses
Statistical analysis was performed using SPSS 12.0
SPSS Inc., Chicago IL). The Kolmogorov–Smirnov test
as used to assess whether data were normally distributed.
easurements at each time point were compared using
epeated measures ANOVA for normally distributed data and
riedman analysis of variance by ranks for non-normally
istributed data. Post-hoc analysis of paired time points
as performed using a Bonferroni correction. Categori-al data were analysed by the χ2 test. Data are presented
s mean ± standard deviation or median and interquartile
ange as appropriate. Statistical significance was assigned at
< 0.05.
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Fig. 2. (a) Plaque index in the carotid arteries was reduced in response to statin treatment. Significant reductions were observed between baseline and 3 months
but not between 3 and 12 months (* indicates P < 0.05 vs. baseline). (b) T2 weighted magnetic resonance image of the common carotid arteries (arrows)
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usage was not changed at 12 months (19/24 versus 18/24:
χ2 = 0.11;P = 0.74). There was no significant change in either
blood pressure or heart rate over the course of the study
(Table 3).
Table 1
Baseline characteristics of patients
Number of subjects (M/F) 24 (20/4)
Age (years) 66.0 ± 8.7
Weight (kg) 80.0 ± 11.6
Body mass index (kg/m2) 26.9 ± 3.6
History of diabetes (%) 2 (8%)
History of hypertension (%) 11 (46%)
History of smoking (%) 15 (63%)
Statin treatment
Simvastatin 40 mg daily (%) 15 (63%)
Simvastatin 10–20 mg daily (%) 5 (21%)
Atorvastatin 10 mg daily (%) 4 (17%)emonstrating bilateral non-obstructive common carotid plaques. (c) Chan
easured at 12 months.
. Results
.1. Clinical and biochemical measures
Baseline characteristics of the 24 patients who completed
ll three study time points are shown in Table 1. The most
ommon statin dose used was simvastatin 40 mg daily (63%
atients); other statin prescriptions are detailed in Table 1.
ean baseline total cholesterol was 187.9 mg/dL (LDL-C
12.7 mg/dL), however 3 months after commencing statins
ean LDL-C was reduced by 37% to 70.8 mg/dL (P < 0.01)
ith a corresponding 24% (P < 0.01) reduction in apoB.
ean LDL-C at 12 months (79.3 g/dL) appeared slightly
reater than at 3 months, but this was not statistically sig-
ificant. Triglycerides and CRP did not change significantly
t 3 or 12 months, though HDL cholesterol did show signif-
cant increase by 12 months – lipid and apolipoprotein data
re shown in Table 2.
Compared to baseline, at 3 months there were no sig-
ificant changes in the proportion of patients taking either
ngiotensin converting enzyme inhibitors (12/24 versus 8/24:
2
= 0.77; P = 0.38) or beta adrenoceptor blockers (22/24 ver-
us 18/24: χ2 = 1.35; P = 0.25). By 12 months, the number
f patients taking ACE inhibitors had increased signifi-
Claque index (ΔPI) at 3 months was significantly correlated to the change
antly compared to baseline (17/24 versus 8/24: χ2 = 5.3;
< 0.05), though this would not have influenced the study
ndings at the early time point of 3 months. Beta blockeroncomitant medication
ACE-inhibitor or angiotensin-II blocker 8 (33%)
Beta-blocker 18 (75%)
Aspirin 20 (83%)
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Table 2
Lipid measures and C-reactive protein
Baseline 3 months 12 months
Total-C (mg/dL) 187.9 ± 41.0 147.2 ± 28.9* 154.2 ± 27.2*
LDL-C (mg/dL) 112.7 ± 38.8 70.8 ± 23.1* 79.3 ± 22.7*
HDL-C (mg/dL) 43.9 ± 16.4 47.8 ± 23.3 49.7 ± 16.2*
Apo B (mg/dL) 90.2 ± 25.1 68.5 ± 15.1* 71.1 ± 15.0*
Apo A-I (mg/dL) 133.9 ± 29.2 132.1 ± 28.1 129.4 ± 23.4
Triglycerides (mg/dL) 157.7 [89.5–201.1] 123.1 [85.9–194.0] 117.8 [78.8–158.5]
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bsCRP (mg/L) 1.8 [1.2–3.0]
* P < 0.01 vs. baseline.
.2. Atherosclerosis regression
All 24 patients had aortic plaque images of sufficient qual-
ty for analysis. Four patients had carotid plaque images at
ne or more time points of insufficient quality for analysis;
herefore they were excluded from statistical analysis. Images
total > 100) from four randomly selected patients were anal-
sed by both observers yielding inter-observer coefficients of
ariation for plaque index of 4.8% in the aorta, and 2.9% in
he carotid. In both the aorta (Fig. 1a) and the carotid arter-
es (Fig. 2a), there were statistically significant reductions in
laque index after 3 months of statin treatment. Mean aor-
ic plaque index decreased from 0.303 ± 0.024 at baseline
o 0.296 ± 0.022 at 3 months (P < 0.05 versus baseline) and
.288 ± 0.024 at 12 months (P < 0.01 versus baseline). Plaque
egression in the aorta between 3 and 12 months was also
ignificant (P < 0.05). In the carotid artery, plaque index fell
rom 0.446 ± 0.053 at baseline to 0.432 ± 0.046 at 3 months
P < 0.05 versus baseline) and 0.416 ± 0.032 at 12 months
P < 0.01 versus baseline). Plaque index for the carotid artery
etween 3 and 12 months did not show significant reduction
P = 0.09). The number of patients with early regression in the
orta at 3 months compared to baseline was 18/24, similar to
hat at 12 months where 20/24 showed regression (χ2 = 0.126,
= 0.72) (Fig. 1c). The number of patients with measurablearly regression at 3 months in the carotid was 14/20, which
as not significantly different to the 18/20 observed at 12
onths (χ2 = 1.4, P = 0.24); see Fig. 2c. Furthermore within
able 3
arameters of vascular function
Baseline 3 months 12 months
ortic distensibility
Ascending 1.86 ± 1.23 2.56 ± 2.05* 2.41 ± 1.31*
Proximal descending 2.36 ± 1.24 3.00 ± 1.44* 3.16 ± 1.52*
Distal descending 3.56 ± 2.19 4.34 ± 2.77** 5.40 ± 2.68*
rachial artery (%Δ)
FMD 8.6 ± 4.6 11.4 ± 5.5* 13.7 ± 5.4*
GTN 31.6 ± 16.5 35.6 ± 17.2 40.6 ± 11.3*
eart rate (bpm) 57 ± 9 55 ± 10 55 ± 8
ystolic BP (mmHg) 130 ± 17 127 ± 19 124 ± 14
iastolic BP (mmHg) 77 ± 12 75 ± 11 74 ± 9
* P < 0.05 vs. baseline.
** P = 0.05 vs. baseline.
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atients, the early (3 months) change in plaque index of aorta
nd carotid arteries showed significant correlation with the
nal change observed at 12 months (Figs. 1c and 2c).
Mean aortic lumen area was 431 ± 77 mm2 at baseline,
34 ± 77 mm2 at 3 months (P = 1.0 versus baseline) and
42 ± 85 mm2 at 12 months (P = 0.09 versus baseline). Mean
umen area in the carotid arteries was 44 ± 9 mm2 at base-
ine, 44 ± 8 mm2 at 3 months (P = 1.0 versus baseline) and
3 ± 8 mm2 at 12 months (P = 0.55 versus baseline).
.3. Physiological measures
After 3 months of statin treatment, aortic distensibility
ncreased by >20% at each of the three locations along its
ength. This effect was sustained but did not increase further at
2 months (Table 3). Flow-mediated dilatation of the brachial
rtery, a measure of endothelial function, also improved after
months by >30% (Table 3). Endothelial independent relax-
tion induced by GTN was not significantly changed after 3
onths, but did show a significant increase by 12 months.
.4. Relationship between variables
Within individual patients there was no correlation
etween MRI quantification of atheroma burden in the aorta
nd carotid at baseline. Although at a group level, endothe-
ial function and aortic compliance improved and atheroma
urden diminished, there was no correlation of these changes
ithin individual patients. Furthermore, there were no sig-
ificant associations between measures of vascular function
r atheroma burden and any of: attained LDL-C; change in
DL-C, HDL-C, apoB, apoA-I, or CRP.
. Discussion
In this study, we have observed that regression of
therosclerosis in response to statin treatment can occur ear-
ier than previously appreciated in both the aorta and carotid
rteries. The robustness of this observation is enhanced by
he finding that, within individual patients, regression at the
arly time point of 3 months was closely related to the mag-
itude and direction of change at 12 months. Patients also
howed early and sustained improvement in aortic disten-
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ibility and in flow mediated vasodilatation of the brachial
rtery.
The magnitude of atheroma regression observed in our
tudy after 3 months is consistent with previous longer-term
tudies of regression in response to statin treatment [6,7,25].
lesser LDL-C reduction than that achieved in our study was
ot associated with early plaque regression after 6 months
tatin treatment [6]. Intensive LDL-C reduction has been
eported to achieve greater regression, but this study did
ot include an early time point [7]. Thus, the early regres-
ion observed here is a new finding that accords with the
nalysis of Nissen et al. [5] in which atheroma regression,
ssessed by intravascular ultrasound in the coronary arter-
es, was predicted by attained mean LDL-C < 70 mg/dL. A
ecent observational study reported overall carotid wall area
rogression by 2.2% per year [8], although individual cases of
egression of up to 7.9% were reported. Importantly, the pop-
lation in that study differed by the inclusion of older patients
ith a higher prevalence of hypertension and selected only
atients with carotid plaques of ≥50% stenosis on a prior
uplex scan.
Mean lumen size of the aorta and carotid appeared to
how slight increase by 12 months, this did not reach sta-
istical significance implying that regression was occurring
redominantly by reversal of ‘positive’ vessel remodelling as
uggested by Corti et al. [6]. There was significant change in
laque index between 3 and 12 months in the aorta, whilst
he carotid artery showed a trend that did not reach signifi-
ance (P = 0.09) over the same time period. This could reflect
he smaller size of the carotid artery compared to the carotid,
aking a small change harder to detect. Alternatively the
laques in the aorta and carotid may differ in composition,
ith certain elements of the plaque likely to be more suscep-
ible to removal than others. For instance, lowering plasma
DL-C could slow the rate of lipoprotein deposition in the
rterial wall, allowing reverse cholesterol transport mecha-
isms to predominate, culminating in net regression [26].
ifferent effects on individual plaque components is sug-
ested by MRI studies of advanced carotid atherosclerosis
n which patients treated with aggressive lipid lowering ther-
py showed a reduction in size of lipid rich areas [27,28].
his study was not designed to examine plaque composi-
ion, though initiation of study to address this question has
ecently been reported [29]. New developments such as lipid
elective contrast agents or higher field strength (3 T) imaging
ith improved resolution might further establish the degree
o which plaque regression involves lipid removal [30,31].
Early clinical benefits of statins have also been ascribed
o anti-inflammatory effects [32]. The degree of change
n coronary atheroma volume measured using intravascular
ltrasound has been related to the magnitude of change in
oth LDL and CRP [33]. However, in the present study, the
arly changes in plaque size occurred in the absence of sig-
ificant change in CRP. Lack of measurable change in CRP
robably reflects both the relatively small sample size, and the
ow baseline CRP level in this stable CAD population, com-
P
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arable to the post treatment CRP levels in other studies [34].
e also found no relationship between the LDL-C attained
nd change in plaque size, which may again reflect the sam-
le size and a clustering of LDL-C levels in the lower range
recluding observation of a quantitative effect. However, the
bsence of changes in biochemical parameters despite plaque
egression highlights the complementary role of MRI as an
maging biomarker.
Rapid improvements in endothelial vasomotor func-
ion have previously been demonstrated in patients with
therosclerosis within weeks [12,14] or even days [13] of
tarting statin treatment. Thus our finding of increased flow
ediated dilatation at 3 months was not surprising. By con-
rast, timing of statin effects on central arterial stiffness is
ess established. Improvements in large artery stiffness have
een demonstrated after a year of statin treatment [35,36],
lthough a shorter study of 8 weeks pravastatin treatment in
atients with familial hypercholesterolemia did not show any
mprovement [37]. Hypertensive patients without coronary
rtery disease treated with high dose atorvastatin (mean LDL
f <70 mg/dL) did show improvements in large artery stiff-
ess after 3 months [38]. Our finding of rapid improvement
n aortic stiffness was of similar magnitude and extends this
otentially beneficial effect of statin treatment to a coronary
rtery disease population. We also observed that GTN medi-
ted (endothelium independent) dilatation of the brachial
rtery was increased after 12 months statin treatment, as has
een previously reported [39,40] and which might reflect
ownstream statin effects e.g. on smooth muscle cell sen-
itivity to nitric oxide.
We initially hypothesised that changes in arterial func-
ion might predict changes in structural parameters, but in
his study we found no correlation on an individual patient
asis between changes is structure and function. Endothelial
unction, aortic stiffness and atheroma burden all represent
ifferent aspects and stages of disease. Although at a popu-
ation level all these parameters may change in a favourable
irection in response to treatment, individual patients may
how variable response in each according to their stage of
isease. As a result, it is likely that measures of vascular
tructure and function will provide complementary insights
nto vascular disease [18].
The capability of MRI to perform non-invasive assessment
f changes in the arterial wall using relatively small numbers
f patients is highlighted by this and other studies [6,22].
ccurate and reproducible assessment of the vessel wall is
ey to detection of atherosclerosis progression or regression
41]. The rationale for this approach has been illustrated by
revious carotid intima-media thickness or coronary IVUS
tudies [42–44]. An early appreciation of effects on both
tructure and function, as provided by MRI, could be used to
uide selection of novel agents prior to investment in major
hase III trials [45]. MRI is an emerging technique and unlike
ltrasound measures of IMT and FMD, has not yet been
alidated as a means to predict future events in large stud-
es. However, recent data shows correlation of aortic plaque
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urden by MRI with clinical risk scores [46]. As our find-
ngs suggest MRI potentially offers additional value through
he assessment of arterial structure in multiple locations and
omplementary measures of vascular function. Therefore, it
eems increasingly likely MRI will play a key role in evalua-
ion of new and existing therapies and may even become part
f individual patient risk assessment.
.1. Study limitations
A potential limitation of this study is the absence of a
ontrol group. However, given strong evidence of the bene-
ts of early and intensive treatment with statins, a placebo
ontrolled arm or even low intensity statin-treatment arm
as not considered ethical. In common with several recent
tudies [5,6], we therefore conducted a longitudinal study of
hanges compared to baseline. As a result, it is not possible
o exclude the possibility that the changes observed were due
o an unknown factor, though in context, this is improbable.
hese patients were newly diagnosed with coronary artery
isease, some of whom were taking vasoactive drugs such as
CE inhibitors and beta adrenoceptor blockers for hyperten-
ion prior to study enrolment. However, the increase in use
f such medications between study baseline and the 3-month
ime point was small and not statistically significant and so
he vascular changes observed over that period are not likely
o be confounded by changes in these other medications. The
–3% reductions in plaque index observed in this study at 3
onths appear relatively modest when compared to decreases
n lesion size of greater than 30% observed over a similar time
rame in some animal studies. However, the interventions
n animal models of atherosclerosis usually involve much
ore extreme changes in lipid levels than those achievable
y statin treatment in humans. Thus, whilst statin treatment
o achieve effective LDL-C reduction appears important for
laque regression, additional HDL-C based interventions in
rder to enhance reverse cholesterol transport may prove even
ore effective [26]. The patient population studied was over-
helmingly male and Caucasian therefore the findings may
ot be applicable across all population groups.
. Conclusions
This study shows that in a population of statin naı¨ve, clini-
ally stable but otherwise unselected coronary artery disease
atients, cholesterol reduction using statins to mean LDL-C
f approximately 70 mg/dL was associated with rapid regres-
ion of atheroma at 3 months. Early changes were highly
orrelated with changes after 12 months. These rapid struc-
ural changes were accompanied by early improvements in
rterial stiffness and endothelial function that were sustained
o 12 months. Use of multi-modal vascular MRI to detect
arly changes in atheroma and vascular function in small
umbers of patients could prove to be an efficient strategy to
creen novel anti-atherosclerotic agents.
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